{"id":"W4416588990","doi":"10.1016/j.conctc.2025.101574","title":"Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease","year":2025,"lang":"en","type":"article","venue":"Contemporary Clinical Trials Communications","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Western University","funders":"Envision; Allergan; Celltrion; Celgene; Amgen; Pfizer; Viropharma; Biogen","keywords":"Vedolizumab; Disease; Phases of clinical research; Phase (matter); Maximum tolerated dose","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01258222,0.0001685975,0.0007348637,0.0001459107,0.0001650668,0.00004379451,0.000615239,0.00009320147,0.000002710992],"category_scores_gemma":[0.005805015,0.0001228273,0.0001517261,0.0002370214,0.0003778639,0.00002035148,0.0002520948,0.0001888813,3.971634e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001494795,"about_ca_system_score_gemma":0.0007557774,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004339913,"about_ca_topic_score_gemma":0.0002840476,"domain_scores_codex":[0.9907085,0.006769034,0.001914915,0.0003477978,0.0001400379,0.0001196657],"domain_scores_gemma":[0.9893154,0.008393909,0.0005728552,0.001389909,0.0002525795,0.00007533615],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9425803,0.01484594,0.03684761,0.00004051528,0.0005753388,0.00001688915,0.000631104,0.0003061845,0.00006708856,0.001406894,0.0002576298,0.002424524],"study_design_scores_gemma":[0.9235904,0.0008665494,0.06683592,0.00008344896,0.0003372954,2.321327e-7,0.001984812,0.004591256,0.00003181478,0.001125851,0.0003717797,0.0001806724],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9642554,0.001627793,0.008767378,0.00132016,0.00007205131,0.02379274,0.00003525575,0.00001003408,0.0001191827],"genre_scores_gemma":[0.9939725,0.0002532685,0.000471777,0.0001332969,0.00002782087,0.004902689,0.0001551814,0.00001433375,0.00006914128],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02998831,"threshold_uncertainty_score":0.6949564,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2741327899154942,"score_gpt":0.4753525915857392,"score_spread":0.201219801670245,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}